Lapatinib Promotes Apoptosis in Hepatoma Cells by Regulating SPP1 Expression

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Liver hepatocellular carcinoma (LIHC) is a significant global health concern.
• The precise mechanisms of targeted therapies like lapatinib in LIHC require further elucidation.
• Secreted phosphoprotein 1 (SPP1) is implicated in various cancers, but its role in LIHC is not fully understood.

Purpose of the Study:

• To investigate the role of SPP1 in LIHC progression and patient prognosis.
• To explore the anti-tumor effects of lapatinib on SPP1 expression in LIHC.
• To elucidate the molecular mechanisms by which lapatinib exerts its effects in LIHC.

Main Methods:

• Analysis of The Cancer Genome Atlas (TCGA) and GSE6764 datasets for SPP1 expression in LIHC.
• Evaluation of SPP1 expression and its correlation with patient survival outcomes.
• In vitro studies using HepG2 cells to assess lapatinib's effects on SPP1 levels, cell proliferation (CCK-8 assay), and apoptosis (Western blotting for BAX/Bcl2 ratio).

Main Results:

• SPP1 expression was significantly higher in LIHC tissues compared to normal liver tissues (P < 0.01).
• Elevated SPP1 levels correlated with inferior patient survival outcomes in LIHC (P < 0.05).
• Lapatinib treatment reduced SPP1 expression, inhibited HepG2 cell proliferation, increased the BAX/Bcl2 ratio, and induced apoptosis.

Conclusions:

• SPP1 is a potential biomarker for disease progression and survival in LIHC patients.
• Lapatinib demonstrates anti-tumor activity in LIHC by downregulating SPP1 expression.
• Lapatinib promotes apoptosis in hepatoma cells, contributing to its therapeutic effect in LIHC.